Charles Schwab’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.8M | Sell |
2,015,577
-165,243
| -8% | -$227K | ﹤0.01% | 2622 |
|
|
2025
Q4 | $3.51M | Buy |
2,180,820
+10,539
| +0.5% | +$22.1K | ﹤0.01% | 2585 |
|
|
2025
Q3 | $5.92M | Buy |
2,170,281
+1,421,266
| +190% | +$4.73M | ﹤0.01% | 2360 |
|
|
2025
Q2 | $2.73M | Buy |
749,015
+126,101
| +20% | +$346K | ﹤0.01% | 2577 |
|
|
2025
Q1 | $1.2M | Buy |
622,914
+36,204
| +6% | +$73.9K | ﹤0.01% | 2780 |
|
|
2024
Q4 | $1.11M | Buy |
586,710
+18,043
| +3% | +$31.3K | ﹤0.01% | 2880 |
|
|
2024
Q3 | $751K | Sell |
568,667
-2,307
| -0.4% | -$3.08K | ﹤0.01% | 3011 |
|
|
2024
Q2 | $582K | Buy |
570,974
+491,170
| +615% | +$607K | ﹤0.01% | 3130 |
|
|
2024
Q1 | $146K | Hold |
79,804
| – | – | ﹤0.01% | 3270 |
|
|
2023
Q4 | $99K | Hold |
79,804
| – | – | ﹤0.01% | 3348 |
|
|
2023
Q3 | $91K | Hold |
79,804
| – | – | ﹤0.01% | 3364 |
|
|
2023
Q2 | $73K | Hold |
79,804
| – | – | ﹤0.01% | 3374 |
|
|
2023
Q1 | $44.7K | Sell |
79,804
-52,566
| -40% | -$40.2K | ﹤0.01% | 3366 |
|
|
2022
Q4 | $76.4K | Hold |
132,370
| – | – | ﹤0.01% | 3293 |
|
|
2022
Q3 | $42K | Buy |
+132,370
| New | +$51.9K | ﹤0.01% | 3368 |
|
|
2022
Q2 | – | Sell |
-476,974
| Closed | -$343K | – | 3542 |
|
|
2022
Q1 | $343K | Buy |
476,974
+33,016
| +7% | +$70.6K | ﹤0.01% | 3182 |
|
|
2021
Q4 | $1M | Hold |
443,958
| – | – | ﹤0.01% | 2908 |
|
|
2021
Q3 | $1.28M | Sell |
443,958
-658,251
| -60% | -$1.88M | ﹤0.01% | 2792 |
|
|
2021
Q2 | $4.18M | Buy |
1,102,209
+87,275
| +9% | +$294K | ﹤0.01% | 2435 |
|
|
2021
Q1 | $3.44M | Buy |
1,014,934
+58,925
| +6% | +$212K | ﹤0.01% | 2472 |
|
|
2020
Q4 | $2.68M | Buy |
956,009
+13,633
| +1% | +$39.8K | ﹤0.01% | 2514 |
|
|
2020
Q3 | $2.37M | Sell |
942,376
-104,548
| -10% | -$917K | ﹤0.01% | 2436 |
|
|
2020
Q2 | $14.2M | Buy |
1,046,924
+304,312
| +41% | +$3.15M | 0.01% | 1408 |
|
|
2020
Q1 | $5.63M | Buy |
742,612
+13,991
| +2% | +$109K | ﹤0.01% | 1776 |
|
|
2019
Q4 | $4.61M | Buy |
728,621
+26,565
| +4% | +$126K | ﹤0.01% | 2058 |
|
|
2019
Q3 | $2.75M | Buy |
702,056
+53,303
| +8% | +$228K | ﹤0.01% | 2268 |
|
|
2019
Q2 | $3.14M | Buy |
648,753
+81,813
| +14% | +$465K | ﹤0.01% | 2186 |
|
|
2019
Q1 | $4.64M | Buy |
566,940
+6,680
| +1% | +$45.8K | ﹤0.01% | 2009 |
|
|
2018
Q4 | $3.1M | Buy |
560,260
+210,638
| +60% | +$1.65M | ﹤0.01% | 2152 |
|
|
2018
Q3 | $3.09M | Sell |
349,622
-32,890
| -9% | -$294K | ﹤0.01% | 2267 |
|
|
2018
Q2 | $3.82M | Buy |
382,512
+36,391
| +11% | +$364K | ﹤0.01% | 2136 |
|
|
2018
Q1 | $3.3M | Buy |
346,121
+49,990
| +17% | +$699K | ﹤0.01% | 2139 |
|
|
2017
Q4 | $4.4M | Buy |
296,131
+57,798
| +24% | +$959K | ﹤0.01% | 1982 |
|
|
2017
Q3 | $4.69M | Buy |
238,333
+31,857
| +15% | +$490K | ﹤0.01% | 1905 |
|
|
2017
Q2 | $2.97M | Buy |
206,476
+81,346
| +65% | +$1.03M | ﹤0.01% | 2080 |
|
|
2017
Q1 | $1.15M | Buy |
125,130
+7,353
| +6% | +$71.8K | ﹤0.01% | 2382 |
|
|
2016
Q4 | $1.23M | Buy |
117,777
+6,622
| +6% | +$57K | ﹤0.01% | 2362 |
|
|
2016
Q3 | $1.01M | Buy |
111,155
+5,722
| +5% | +$48.6K | ﹤0.01% | 2410 |
|
|
2016
Q2 | $789K | Buy |
105,433
+1,764
| +2% | +$15.4K | ﹤0.01% | 2423 |
|
|
2016
Q1 | $935K | Buy |
103,669
+39,857
| +62% | +$323K | ﹤0.01% | 2372 |
|
|
2015
Q4 | $825K | Buy |
63,812
+1,625
| +3% | +$16.6K | ﹤0.01% | 2452 |
|
|
2015
Q3 | $601K | Buy |
62,187
+17,507
| +39% | +$161K | ﹤0.01% | 2552 |
|
|
2015
Q2 | $460K | Buy |
44,680
+23,785
| +114% | +$203K | ﹤0.01% | 2699 |
|
|
2015
Q1 | $233K | Buy |
20,895
+9,395
| +82% | +$100K | ﹤0.01% | 2916 |
|
|
2014
Q4 | $134K | Sell |
11,500
-5,419
| -32% | -$77.7K | ﹤0.01% | 3034 |
|
|
2014
Q3 | $375K | Buy |
16,919
+306
| +2% | +$7.03K | ﹤0.01% | 2693 |
|
|
2014
Q2 | $462K | Buy |
+16,613
| New | +$400K | ﹤0.01% | 2655 |
|
Other funds holding AKBA
VCM
VPM
Charles Schwab's AKBA Position: Q1 2026 in Review
Charles Schwab reduced its Akebia Therapeutics (AKBA) stake by 7.6% in Q1 2026, selling an estimated $227K and leaving 2,015,577 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2622.
Charles Schwab first reported a position in AKBA in Q2 2014 and has held it in 47 quarters since. The position peaked at $14.2M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Charles Schwab held 2,015,577 shares of Akebia Therapeutics worth $2.8M as of Q1 2026.
- Charles Schwab sold 165,243 Akebia Therapeutics shares in Q1 2026, an estimated $227K.
- Akebia Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2622 holding.
- Charles Schwab first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 47 quarters since.
- Charles Schwab's Akebia Therapeutics position peaked at $14.2M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.